Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Lapatinib in Pediatric Ependymoma
NCT00883688Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2009
- Primary completion
- Apr 2015
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and lapatinib in ependymoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 1 year. Started Jul 2009; status: completed.
02
Drugs
bevacizumablapatinib
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT00883688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883688.